MedTrace Logo

Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate

NCT03051620 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 142

Last updated 2021-03-18

Study results available
· View outcomes & findings →

Summary

The study is a cohort study comprising 136 patients with osteoporosis stopping treatment with alendronate. The study will contribute with new knowledge about biochemical markers of bone turnover as predictors of bone loss after stopping treatment with alendronate.

Conditions

Interventions

DRUG

Discontinue alendronate

136 patients with osteoporosis stopping treatment with alendronate.

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Bente L Langdahl, MD PhD DMSc · Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2019-01-31
Completion
2019-01-31
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03051620 on ClinicalTrials.gov